Form 4: Kezar Life Sciences COO Sells Shares for Tax Obligations

Sentiment:

Insider Transaction Report


Kezar Life Sciences' Chief Operating Officer, Mark C. Schiller, sold 561 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

  • Mark C. Schiller, Chief Operating Officer of Kezar Life Sciences, Inc. (KZR), reported a transaction involving the company's common stock.
  • On July 2, 2025, 561 shares of common stock were disposed of at a price of $4.28 per share.
  • This sale was explicitly stated as being required to cover statutory tax withholding obligations in connection with the vesting of restricted stock units.
  • The transaction does not represent a discretionary sale by Mr. Schiller.
  • Following this transaction, Mr. Schiller beneficially owns 2,739 shares of Kezar Life Sciences common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes related to RSU vesting, which is a neutral event for the company's operational or financial outlook.

Positives

  • The transaction represents a non-discretionary "sell to cover" sale, indicating it was for tax withholding purposes related to restricted stock unit vesting rather than a voluntary sale by the officer.
  • The underlying event is the vesting of restricted stock units, which typically signifies the achievement of performance milestones or continued service by the executive.

Negatives

  • The transaction resulted in a reduction of 561 shares from the Chief Operating Officer's direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

  • Shareholders: The sale represents a minor reduction in insider ownership, but its non-discretionary nature mitigates any negative sentiment typically associated with insider sales.
  • Employees: The vesting of restricted stock units is a positive event for the Chief Operating Officer, representing compensation and retention.

Key Dates

DateDescription
07/02/2025Date of transaction (sale of common stock)
07/03/2025Date the Form 4 was signed by the attorney-in-fact

Keywords

Kezar Life Sciences, KZR, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Mark C. Schiller, Officer Transaction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.